$1,157.21
0.33% today
Nasdaq, Sep 16, 08:44 pm CET
ISIN
US75886F1075
Symbol
REGN
Sector
Industry

Regeneron Pharmaceuticals Stock price

$1,153.35
-4.98 0.43% 1M
+187.88 19.46% 6M
+275.06 31.32% YTD
+327.10 39.59% 1Y
+513.83 80.35% 3Y
+871.73 309.54% 5Y
+807.32 233.31% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
-11.11 0.95%
ISIN
US75886F1075
Symbol
REGN
Sector
Industry

Key metrics

Market capitalization $127.12b
Enterprise Value $120.01b
P/E (TTM) P/E ratio 30.54
EV/FCF (TTM) EV/FCF 36.05
EV/Sales (TTM) EV/Sales 8.90
P/S ratio (TTM) P/S ratio 9.42
P/B ratio (TTM) P/B ratio 4.51
Revenue growth (TTM) Revenue growth 6.46%
Revenue (TTM) Revenue $13.49b
EBIT (operating result TTM) EBIT $4.11b
Free Cash Flow (TTM) Free Cash Flow $3.33b
Cash position $9.82b
EPS (TTM) EPS $37.76
P/E forward 30.50
P/S forward 8.97
EV/Sales forward 8.47
Short interest 2.01%
Show more

Create a Free Account to create an Regeneron Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Regeneron Pharmaceuticals Stock Analysis

Analyst Opinions

28 Analysts have issued a Regeneron Pharmaceuticals forecast:

20x Buy
71%
6x Hold
21%
2x Sell
7%

Analyst Opinions

28 Analysts have issued a Regeneron Pharmaceuticals forecast:

Buy
71%
Hold
21%
Sell
7%

Financial data from Regeneron Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
13,489 13,489
6% 6%
100%
- Direct Costs 2,320 2,320
10% 10%
17%
11,169 11,169
6% 6%
83%
- Selling and Administrative Expenses 2,368 2,368
19% 19%
18%
- Research and Development Expense 4,234 4,234
13% 13%
31%
4,567 4,567
5% 5%
34%
- Depreciation and Amortization 453 453
15% 15%
3%
EBIT (Operating Income) EBIT 4,114 4,114
7% 7%
30%
Net Profit 4,322 4,322
1% 1%
32%

In millions USD.

Don't miss a Thing! We will send you all news about Regeneron Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Regeneron Pharmaceuticals Stock News

Neutral
GlobeNewsWire
3 days ago
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps Dupixent is the leading biologic medicine for all five FDA-approved indications in new-to-brand prescriptions TARRYTOWN, N.Y. and PARIS, Sept.
Neutral
GlobeNewsWire
5 days ago
Three new post-hoc analyses highlight EYLEA HD rapid and sustained fluid control and consistent safety profile over two years in patients with wet age-related macular degeneration (wAMD)
Positive
The Motley Fool
5 days ago
These two drugmakers have been delivering significantly above-average returns for years. Both still have excellent prospects and could decide to split their stocks as their share prices get higher.
More Regeneron Pharmaceuticals News

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Head office United States
CEO Leonard Schleifer
Employees 13,450
Founded 1988
Website www.regeneron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today